ATOSSA THERAPEUTICS, INC. Annual Report Summary

I’ve put together this guide to help you understand how Atossa Therapeutics performed this year. Think of this as a plain-English breakdown of where the company stands, rather than a dense legal filing.

1. What does this company do?

Atossa is a Seattle-based biotech company in the research phase. Because they have no products on the market, they generate no sales revenue. Their mission is to develop new treatments for cancer and women’s health.

Their lead drug, (Z)-endoxifen, is a pill designed to treat breast cancer. Many patients take tamoxifen, but it must be processed by the liver to work. About 30% of people cannot process it correctly. Atossa’s drug is already in its active form, so it works for everyone regardless of their liver enzymes.

2. How is the science progressing?

This year, the company focused on two main clinical trials:

• Karisma Study (Phase 2): This study tests if (Z)-endoxifen can reduce breast density, a known cancer risk factor. With 225 participants, the results were promising. The 1 mg dose reduced density by 17.3%, and the 2 mg dose reduced it by 23.5%. The placebo group saw almost no change. Atossa expects to release final data in early 2026.
• I-SPY 2 Study (Phase 2): This trial tests the drug on patients with high-risk, early-stage breast cancer. Participants saw a 72% reduction in tumor size. Atossa is now testing the drug alongside standard treatments. They expect to report more data in late 2026.

3. Financial health: The "Burn Rate"

At the end of the year, Atossa had about $23.4 million in cash. They spent $15.8 million this year on trials, patient enrollment, and manufacturing. At this rate, their cash will last into 2027.

Since they have no revenue, they fund operations by selling more stock. This creates more shares, which reduces your ownership percentage in the company.

4. Major risks to watch

• Clinical Trial Failure: (Z)-endoxifen has not yet passed large-scale Phase 3 trials. If the 2026 data is poor, the company’s value could drop significantly.
• Regulatory Hurdles: The FDA requires strict proof of safety and effectiveness. Even with good early results, there is no guarantee the FDA will approve the drug.
• Dilution: Because the company has no revenue, they must sell more stock to survive. This lowers the value of your existing shares and often puts downward pressure on the stock price.
• Market Sensitivity: This is a small, volatile company. Its stock price can swing wildly based on general biotech trends, interest rates, and speculative trading.

5. The Bottom Line

Atossa is a high-risk, high-reward investment. You aren't buying a company with current profits; you are betting on the success of (Z)-endoxifen. If the drug succeeds in 2026, a larger pharmaceutical company might buy them out. However, if the program fails, the company has little else to fall back on, which could lead to a total loss of your investment.

Investor Tip: Before investing, consider whether your portfolio can handle the volatility of a company that relies entirely on future clinical trial results. If you are looking for steady dividends or established revenue, this type of speculative biotech may not be the right fit for your strategy.